Table 6.
Median age (Inter Quartile Range) Incidence rates (crude and age-standardized), sex-rate ratios, and 5-year overall survival (OS) and relative survival (RS) estimates (95% Confidence intervals) for polycythaemia vera, essential thrombocythaemia, and myleoproliferative neoplasms unclassified: Haematological Malignancy Research Network diagnoses Sept 2006 to Aug 2009, Sept 2011 to Aug 2013, followed through to September 2015.
| Polycythaemia vera |
Essential thrombocythaemia |
Myleoproliferative (MPN) Unclassifiable |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | Males | Females | All patients | Males | Females | All patients | Males | Females | ||
| Total diagnoses | 310 | 140 | 170 | 663 | 289 | 374 | 120 | 70 | 50 | |
| Median age (IQR) | 70.5 (61.4 −78.6) | 65.3 (58.8–76.4) | 73.1 (65.4–80.9) | 71.5 (60.5–80.8) | 71.0 (60.3–80.0) | 72.2 (60.6–81.8) | 72.3 (64.2–80.1) | 72.3 (63.0–80.1) | 73.8 (65.6–81.7) | |
| Crude rate per 100,000 | 1.74 (1.55–1.94) | 1.62 (1.36–1.91) | 1.85 (1.58–2.15) | 3.71 (3.44–4.01) | 3.34 (2.97–3.75) | 4.06 (3.66–4.5) | 0.67 (0.56–0.8) | 0.81 (0.63–1.02) | 0.54 (0.40–0.72) | |
| Age-standardized rates per 100,000 | European 2013 | 2.06 (1.95–2.16) | 2.09 (1.93–2.25) | 1.99 (1.84–2.13) | 4.35 (4.20–4.50) | 4.57 (4.33–4.82) | 4.31(4.11–4.51) | 0.79 (0.72–0.87) | 1.12 (0.98–1.26) | 0.58 (0.49–0.66) |
| European 1976 | 1.36 (1.29–1.44) | 1.44 (1.33–1.56) | 1.27 (1.17–1.37) | 2.84 (2.74–2.94) | 2.85 (2.70–3.00) | 2.91 (2.76–3.05) | 0.5 (0.45–0.56) | 0.69 (0.59–0.79) | 0.36 (0.30–0.42) | |
| USA | 1.44 (1.37–1.52) | 1.48 (1.37–1.60) | 1.38 (1.28–1.48) | 3.13 (3.02–3.24) | 3.24 (3.07–3.41) | 3.14 (2.99–3.29) | 0.55 (0.50–0.61) | 0.78 (0.67–0.89) | 0.40 (0.33–0.46) | |
| World | 0.93 (0.88–0.98) | 1.00 (0.92–1.09) | 0.85 (0.78–0.93) | 1.97 (1.89–2.04) | 1.92 (1.81–2.03) | 2.04 (1.93–2.16) | 0.35 (0.31–0.39) | 0.48 (0.4–0.56) | 0.25 (0.20–0.29) | |
| Male/female age-standardized (European 2013) sex rate ratio | 1.05 (0.95–1.17) | 1.06 (0.99–1.14) | 1.94 (1.58–2.37) | |||||||
| 5-year overall survival% | 77.68 (72.10–82.27) | 76.71 (68.02–83.33) | 78.49 (70.74–84.40) | 71.19 (67.11–74.86) | 68.41 (61.99–73.98) | 73.34 (67.90–78.02) | 57.98 (47.67–66.96) | 61.25 (47.90–72.15) | 54.26 (37.93–68.01) | |
| 5-year relative survival% | 94.88 (87.46–97.96) | 95.11 (77.92–99.0) | 95.16 (81.37–98.81) | 93.55 (87.95–96.60) | 92.55 (81.40–97.13) | 93.84 (85.86–97.38) | 75.91 (61.64–85.47) | 81.01 (59.83–91.73) | 68.68 (46.32–83.24) | |